An Evaluation of Psychopathic Traits in Patient MONSANTO (NYSE: MON)
From my confidential clinical records of psychoanalysis conducted
with high-profile clients, password protected, for reference only.
Patient Monsanto (NYSE: MON – the ‘Entity’) was analysed over the
course of several sessions, in which it presented itself as a
disarmingly well-heeled and soft-spoken middle-aged man, wearing a
cardigan and slacks – expensive, but not ostentatiously so – with a warm
smile and firm handshake.
Entity is high functioning and eminently successful – a pillar of its
community and a major asset to its shareholders; even invested in
social responsibility and environmental programmes.
This, in itself, is not inconsistent with the psychopathic profile –
the boldness, disinhibition and lack of empathy as defined in
Christopher J Patrick’s triarchic model of psychopathy can often become
assets in corporate settings, of which the patient is a master.1
While its outward ‘mask’ maintains high conformance to social norms,
over the course of our sessions this mask began to reveal fractures,
apertures into the hidden self within.
As I worked to gain the trust of the Entity, it allowed me to see
sustained flashes of its core, as the therapeutic relationship developed
and the Entity began to see that I would hold externally non-judgmental
space for it to reveal its deeper motivators and complexes.
